These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24071056)

  • 1. Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS+T regulatory and dendritic cells in patients with gliomas.
    Gousias K; von Ruecker A; Voulgari P; Simon M
    J Neuroimmunol; 2013 Nov; 264(1-2):84-90. PubMed ID: 24071056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.
    Heimberger AB; Abou-Ghazal M; Reina-Ortiz C; Yang DS; Sun W; Qiao W; Hiraoka N; Fuller GN
    Clin Cancer Res; 2008 Aug; 14(16):5166-72. PubMed ID: 18698034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy.
    Kavousanaki M; Makrigiannakis A; Boumpas D; Verginis P
    Arthritis Rheum; 2010 Jan; 62(1):53-63. PubMed ID: 20039433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.
    Faget J; Bendriss-Vermare N; Gobert M; Durand I; Olive D; Biota C; Bachelot T; Treilleux I; Goddard-Leon S; Lavergne E; Chabaud S; Blay JY; Caux C; Ménétrier-Caux C
    Cancer Res; 2012 Dec; 72(23):6130-41. PubMed ID: 23026134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eminent role of ICOS costimulation for T cells interacting with plasmacytoid dendritic cells.
    Janke M; Witsch EJ; Mages HW; Hutloff A; Kroczek RA
    Immunology; 2006 Jul; 118(3):353-60. PubMed ID: 16827896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy.
    Rapp M; Ozcan Z; Steiger HJ; Wernet P; Sabel MC; Sorg RV
    J Neurosurg; 2006 Jul; 105(1):41-50. PubMed ID: 16874889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells.
    Witsch EJ; Peiser M; Hutloff A; Büchner K; Dorner BG; Jonuleit H; Mages HW; Kroczek RA
    Eur J Immunol; 2002 Sep; 32(9):2680-6. PubMed ID: 12207353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T
    Löhr M; Freitag B; Technau A; Krauss J; Monoranu CM; Rachor J; Lutz MB; Hagemann C; Kessler AF; Linsenmann T; Wölfl M; Ernestus RI; Engelhardt S; Gelbrich G; Schlegel PG; Eyrich M
    Cancer Immunol Immunother; 2018 Oct; 67(10):1545-1558. PubMed ID: 30054667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.
    Fecci PE; Ochiai H; Mitchell DA; Grossi PM; Sweeney AE; Archer GE; Cummings T; Allison JP; Bigner DD; Sampson JH
    Clin Cancer Res; 2007 Apr; 13(7):2158-67. PubMed ID: 17404100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
    Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand.
    Ito T; Yang M; Wang YH; Lande R; Gregorio J; Perng OA; Qin XF; Liu YJ; Gilliet M
    J Exp Med; 2007 Jan; 204(1):105-15. PubMed ID: 17200410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmacytoid dendritic cells have a cytokine-producing capacity to enhance ICOS ligand-mediated IL-10 production during T-cell priming.
    Ogata M; Ito T; Shimamoto K; Nakanishi T; Satsutani N; Miyamoto R; Nomura S
    Int Immunol; 2013 Mar; 25(3):171-82. PubMed ID: 23125331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.
    Chang CN; Huang YC; Yang DM; Kikuta K; Wei KJ; Kubota T; Yang WK
    J Clin Neurosci; 2011 Aug; 18(8):1048-54. PubMed ID: 21715171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients.
    McCarter MD; Baumgartner J; Escobar GA; Richter D; Lewis K; Robinson W; Wilson C; Palmer BE; Gonzalez R
    Ann Surg Oncol; 2007 Oct; 14(10):2854-60. PubMed ID: 17593331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood.
    Ahn JS; Krishnadas DK; Agrawal B
    Int Immunol; 2007 Mar; 19(3):227-37. PubMed ID: 17289657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma.
    Głowala-Kosińska M; Chwieduk A; Nieckula J; Saduś-Wojciechowska M; Grosicki S; Rusin A; Nowara E; Giebel S
    Eur J Haematol; 2013 Aug; 91(2):122-8. PubMed ID: 23679234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas.
    Elliott LH; Brooks WH; Roszman TL
    J Neurosurg; 1987 Aug; 67(2):231-6. PubMed ID: 2885402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory T-cells are possible effect prediction markers of immunotherapy for cancer patients.
    Wada J; Yamasaki A; Nagai S; Yanai K; Fuchino K; Kameda C; Tanaka H; Koga K; Nakashima H; Nakamura M; Tanaka M; Katano M; Morisaki T
    Anticancer Res; 2008; 28(4C):2401-8. PubMed ID: 18751426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg.
    Biollaz G; Bernasconi L; Cretton C; Püntener U; Frei K; Fontana A; Suter T
    Eur J Immunol; 2009 May; 39(5):1323-33. PubMed ID: 19337997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations.
    Schick J; Vogt V; Zerwes M; Kroell T; Kraemer D; Köhne CH; Hausmann A; Buhmann R; Tischer J; Schmetzer H
    J Immunother; 2013 May; 36(4):223-37. PubMed ID: 23603857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.